We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

14 of 16 severe COVID patients in trial recover with experimental Israeli drug

4 116 256
04.02.2021

Israeli immunotherapy company Enlivex Therapeutics said Wednesday that 16 severe and critical COVID-19 patients who received its experimental treatment had survived a 28-day Phase II clinical trial period.

Two of the patients, who were critical cases at the start of the trial when they received the company’s Allocetra treatment, were still in intensive care and on ventilators at the end of the trial.

The other 14 patients recovered, were discharged from the hospital by the end of the trial and were reported to be healthy. The average duration of hospitalization after receiving Allocetra, for those who were discharged, was 5.3 days, the company said.

Get The Start-Up Israel's Daily Start-Up by email and never miss our top stories Free Sign Up

At the start of the trial, nine of the patients were in severe condition and seven were critical.

The company did a preliminary trial of five COVID-19 patients last fall. All of those patients, who were in severe to critical condition when they received the drug, were released from the hospital with an average stay of under 10 days........

© The Times of Israel


Get it on Google Play